Ultrawide-field indocyanine angiography changes post 12 weeks of eplerenone in central serous chorioretinopathy Authors: Aketi Sagar, Sanjay Mishra, Pradeep Kumar, Alok Sati, Ashutosh Gupta, Abhijeet Avasthi, D Srujana, Supriya Dhar, M Khaleel, Amrita Joshi Published: 2026 ABSTRACT Background:Central serous chorioretinopathy (CSCR) is a pachychoroid-spectrum disease driven by choroidal hyperpermeability. Mineralocorticoid receptor (MR) dysregulation is implicated, and eplerenone, a selective MR antagonist, may reduce leakage. Ultrawide-field indocyanine green angiography (UWF-ICGA) enables panoramic assessment of choroidal vasculature. We evaluated UWF-ICGA changes after 12 weeks of eplerenone and correlated them with functional and anatomical outcomes.Methods:In this prospective, single-center observational study (January 2024 to June 2025), 58 adults with CSCR received Eplerenone (50 mg daily for 1 month, then 25 mg daily for 2 months). Baseline workup included best-corrected visual acuity (BCVA), spectral-domain optical coherence tomography enhanced depth imaging (OCT-EDI), fundus fluorescein angiography (FFA), and UWF-ICGA (OPTOS California). The primary outcome was mean change in the total area of choroidal hyperpermeability (measured in mm2) from baseline to 12 weeks in the mid phase to late phase of ICGA (indocyanine green angiography). Secondary outcome measures included changes in the widest diameters of the ampullas of the supero temporal, supero nasal, infero temporal, and infero nasal vortex veins (in mm) in the early mid phase of ICGA on optos california using built in optos advance software’s planimetry tool, changes in subfoveal choroidal thickness (SFCT) (in microns) on OCT-EDI and measured using its inbuilt planimetry tools, BCVA in logMAR, and presence of sub retinal fluid (SRF) on OCT from baseline to 12 weeks. Paired t-tests and Chi-square tests were applied (α = 0.05).Results:Participants (86.2% male; mean age 39.9 ± 2.6 years) presented acutely (mean 8.8 ± 1.3 days). BCVA improved from 0.24 ± 0.10 to 0.08 ± 0.06 LogMAR (Δ = −0.16 ± 0.09; P < 0.001), with elimination of the poorest visual acuity category (0.28–0.48). The central macular thickness decreased from 540.3 ± 146.5 to 271.3 ± 23.3 µm (Δ = −269.0 ± 145.2; P < 0.001); SRF resolved in 86.2% (P < 0.001). The UWF-ICGA hyperpermeability area fell from 9.62 ± 5.70 to 6.47 ± 4.32 mm² (Δ = −3.15 ± 4.28; P < 0.001). SFCT decreased from 476.8 ± 102.5 to 391.6 ± 24.8 µm (Δ = −85.2 ± 103.4; P < 0.001). Quadrant vortex vein diameters showed small, nonsignificant reductions; the overall mean changed from 1.39 ± 0.17 to 1.35 ± 0.16 mm (P > 0.05).Conclusion:Twelve weeks of eplerenone was associated with significant functional gains and structural recovery in acute CSCR, alongside a measurable reduction in UWF-ICGA hyperpermeability and SFCT. UWF-ICGA offers a sensitive, mechanism-aligned biomarker for monitoring MR-targeted therapy. Central serous chorioretinopathy (CSCR) sits within the pachychoroid spectrum and typically affects young to middle-aged men, presenting with a serous neurosensory retinal detachment and acute complaints of blurred or distorted vision; although often self-limited, many patients relapse or evolve to chronic disease with meaningful quality-of-life impact.[123] Current evidence points to choroidal vascular dysfunction as the principal driver: Hyperpermeable, dilated choroidal vessels leak sub retinal fluid (SRF) into the subretinal space, producing the characteristic detachment. Increasingly, dysregulation of the mineralocorticoid receptor (MR)—expressed in ocular tissues—has been implicated in this permeability shift and in disordered ocular fluid homeostasis.[45] While the etiology of CSCR is multifactorial (stress, exogenous corticosteroids, genetic susceptibility), MR signaling offers a unifying biologic pathway through which aldosterone can enhance vascular permeability and fluid retention, thereby amplifying choroidal leakage in predisposed eyes.[45] Conventional CSCR treatments are variably effective and often do not target the upstream biology. Corticosteroids are generally avoided because of their potential to worsen choroidal hyperpermeability. Thermal laser, photodynamic therapy (PDT), and anti-VEGF agents may benefit selected cases, but these approaches are invasive, carry procedure-related risks, and may not modify the underlying pachychoroid vasculopathy.[5] This therapeutic gap has focused attention on mineralocorticoid antagonism. Eplerenone—a selective MR blocker widely used in cardiology—counteracts aldosterone’s permeability and fluid-retentive effects and therefore represents a mechanistically rational option for CSCR.[67] By attenuating MR-mediated choroidal vascular leakage, eplerenone may normalize retinal–choroidal fluid dynamics and promote resorption of subretinal fluid with parallel functional gains.[7] Because CSCR is fundamentally a choroidal vascular disorder, imaging endpoints that directly interrogate the choroid are valuable for both disease characterization and treatment monitoring. Ultrawide-field indocyanine green angiography (UWF ICGA) provides panoramic visualization of the choroidal circulation far beyond the posterior pole, complementing fluorescein angiography (which primarily images retinal vessels) and standard field Indocyanine green angiography (ICGA).[8] UWF ICGA can depict hallmark pachychoroid features—diffuse choroidal hyperpermeability [Fig. 1], enlarged choroidal vessels [Fig. 2], and peripheral involvement—across a broad field, enabling assessment of disease extent and activity. Prior angiographic work has shown increased choroidal thickness and leakage in CSCR and suggested that angiographic hyperpermeability tracks with clinical phenotype and chronicity.[78] However, systematic evaluation of how these ultrawide-field choroidal signatures evolve after pharmacologic MR antagonism remains limited, especially over standardized treatment intervals. This study investigates UWF ICGA changes after 12 weeks of eplerenone in CSCR. UWF ICGA of the left eye showing focal hypercyanescence in the late phase UWF ICGA of the right eye in inferior gaze showing dilated Vortex veins and its ampulla in a patient of CSCR Methods This prospective, single-center observational study was conducted over a period of 18 months, from January 2024 to June 2025. The study population comprised patients diagnosed with CSCR who were planned for treatment with eplerenone and consented to participate. Patients aged 18 years and above with a confirmed diagnosis of CSCR and prescribed eplerenone therapy were eligible for inclusion. The 12-week study duration was chosen to evaluate the primary outcome of vascular remodeling during the peak treatment phase. Exclusion criteria included the presence of other retinal diseases, significant ocular comorbidities such as choroidal neovascular membrane, media opacities preventing adequate fundus visualization, and any systemic condition that could affect visual outcome. Patients with renal pathology, contraindications to eplerenone therapy, hyperkalemia (serum potassium >5.5 mEq/L), impaired renal function (serum creatinine >2.0 mg/dL in males and >1.8 mg/dL in females), and pregnant and lactating women were excluded. Rationale for the indications for treatment: Although acute CSCR often undergoes spontaneous resolution, this study adopted a pilot approach to evaluate the impact of early pharmacologic intervention with oral eplerenone. The primary indications for treatment in the acute phase (mean duration 8.8 ± 1.3 days) were as follows: (a)Vocational Necessity: Our cohort consisted primarily of active-duty military personnel where rapid visual rehabilitation and resolution of metamorphopsia were essential for maintaining operational readiness.(b)Pilot Approach: This study aimed to evaluate if early mineralocorticoid receptor (MR) antagonism could hasten the resolution of the “pachychoroid” state and prevent the progression to chronicity.(c)Clinical Severity: Patients presenting with clinically significant subretinal fluid (SRF) involving the fovea and associated macular thickening were considered at higher risk for irreversible retinal pigment epithelium (RPE) changes. This clinical presentation justified the decision for early pharmacological intervention to achieve rapid resolution. (a)Vocational Necessity: Our cohort consisted primarily of active-duty military personnel where rapid visual rehabilitation and resolution of metamorphopsia were essential for maintaining operational readiness. Vocational Necessity: Our cohort consisted primarily of active-duty military personnel where rapid visual rehabilitation and resolution of metamorphopsia were essential for maintaining operational readiness. (b)Pilot Approach: This study aimed to evaluate if early mineralocorticoid receptor (MR) antagonism could hasten the resolution of the “pachychoroid” state and prevent the progression to chronicity. Pilot Approach: This study aimed to evaluate if early mineralocorticoid receptor (MR) antagonism could hasten the resolution of the “pachychoroid” state and prevent the progression to chronicity. (c)Clinical Severity: Patients presenting with clinically significant subretinal fluid (SRF) involving the fovea and associated macular thickening were considered at higher risk for irreversible retinal pigment epithelium (RPE) changes. This clinical presentation justified the decision for early pharmacological intervention to achieve rapid resolution. Clinical Severity: Patients presenting with clinically significant subretinal fluid (SRF) involving the fovea and associated macular thickening were considered at higher risk for irreversible retinal pigment epithelium (RPE) changes. This clinical presentation justified the decision for early pharmacological intervention to achieve rapid resolution. The sample size was calculated using the formula N = (Zα/2)² × (pq)/d², assuming a 95% confidence interval and 5% α error. Based on the study by Rajesh et al.,[9] where 81.25% of patients showed a reduction in SRF after eplerenone therapy, the sample size was determined to be 58 eyes. All enrolled patients underwent a detailed baseline evaluation including clinical history, best-corrected visual acuity (BCVA) after refraction, and comprehensive ophthalmic examination. The diagnosis of CSCR was confirmed by clinical examination and spectral-domain optical coherence tomography enhanced depth imaging (SD-OCT-EDI) on Heidelberg Spectralis. Baseline fundus fluorescein angiography (FFA) and Indocyanine green angiography (ICGA) were performed using the Optos California system (Nikon) to identify characteristic features such as areas of focal hypercyanescence [Fig. 1] and dilated vortex veins [Fig. 2]. The images were analyzed for the area of hyperpermeability in the mid to late phase ICGA wherein zones of choroidal hyperpermeability were recognized as areas of increased cyanescence appearing in the mid-phase and persisting into the late phase which were manually delineated by free hand using the inbuilt planimetry tools of Optos Advance to calculate areas in mm2 [Figs. 3-5]. The software automatically calculates the area in square millimeters, accounting for the peripheral distortion inherent in wide-field imaging. UWF ICGA of the left eye in a patient of CSCR showing the area of focal hypercyanescence in the late phase at onset; area was measured 2.4 mm2 on Optos California using Optos advance UWF ICGA of the left eye showing resolving area of focal hypercyanescence in the late phase in the same patient after 12 weeks of eplerenone therapy; area was measured 1.7 mm2 on Optos California using Optos advance measurement tools Demonstration of measurement of area of hyperpermeability on UWF ICGA on optos california using Optos Advance pixel corrected planimetry tools The widest diameter of the ampullas of the supero temporal, supero nasal, infero temporal, and infero nasal vortex veins (in mm) in the early mid-phase of ICGA were measured using the ruler tool of the inbuilt planimetry tools of Optos Advance [Figs. 6-8]. To ensure accuracy, measurements were performed by two independent masked observers, and the mean of the two values was utilized for statistical analysis. The mean of the two measurements was used for analysis to ensure intergrader reliability. UWF ICGA of the left eye in a patient of CSCR showing measurements of diameters of dilated Vortex Vein Ampulla: Superonasal, 1.2 mm; superotemporal, 1.4 mm; infero temporal, 1.6 mm; and inferonasal, 1.5 mm; at onset on Optos California using Optos advance measurement tools UWF ICGA of the left eye showing measurements of diameter of dilated Vortex Vein Ampulla after 12 weeks of treatment with Tab Eplereneone: Superonasal, 1.2 mm; superotemporal, 1.4 mm; infero temporal, 1.5 mm; and inferonasal, 1.4 mm; on Optos California using Optos Advance measurement tools Demonstration of measurement of ampulla diameter on UWF ICGA on Optos California using Optos Advance pixel corrected planimetry tools Eplerenone was administered orally for 3 months, with an initial dose of 50 mg once daily for the first month, followed by 25 mg once daily for the subsequent 2 months. Following completion of treatment, patients were observed for an additional 3 months before study exit. During this 3-month post-treatment observation period, no additional medical or surgical interventions were performed for eyes with persistent SRF to avoid confounding the observational outcomes. Throughout the study, patients were monitored for systemic side effects and underwent baseline and follow-up assessments of pulse rate, blood pressure, serum potassium, and renal function tests. The primary outcome measure was the mean change in the total area of choroidal hyperpermeability (measured in mm2) from baseline to 12 weeks in the mid phase to late of ICGA. Secondary outcome measures included changes in the widest diameter of the ampullas of the supero temporal, supero nasal, infero temporal, and infero nasal vortex veins (in mm) in the early mid phase of ICGA on Optos California using built in Optos Advance software’s planimetry tool, changes in SFCT (in microns) on OCT EDI taken on Heidelberg Spectralis and measured using its inbuilt planimetry manual calipers to measure the sub foveal vertical distance from the outer edge of the retinal pigment epithelium (RPE) to the inner surface of the choroid-sclera junction, changes in BCVA in logMAR, and the presence of SRF on OCT from baseline to 12 weeks. Representative ICGA and OCT images were acquired at baseline and at 6- and 12-week follow-up visits to document changes in hyperpermeability, vortex vein ampulla diameters, and retinal morphology. Data were analyzed using Epi Info™ version 7.2.6 (Centers for Disease Control and Prevention, Atlanta, GA, USA).[10] Descriptive statistics were used to summarize demographic and clinical parameters. Continuous variables were expressed as mean ± standard deviation, while categorical variables were summarized as frequencies and percentages. The dependent t-test was applied to compare pre- and post-treatment continuous variables, and Chi-square test was used for categorical data. A P value < 0.05 was considered statistically significant. Results Fifty-eight CSCR patients (100%) were enrolled, predominantly male (86.2%), with a homogeneous, middle-aged profile (mean 39.9 ± 2.6 years; 36–44 years). Age groups were evenly distributed (36–38: 34.5%; 39–41: 27.6%; 42–44: 37.9%). Left eyes were more frequently affected (67.2% vs 32.8%), and presentations were acute (mean onset 8.8 ± 1.3 days; most commonly 9 days, 36.2%) [Table 1]. Table 1Baseline demographics and clinical characteristicsParameterValuen (%)Total Participants5858 (100%)Age (years)39.9±2.6-Age Range36-44 years-Age Groups 36-38 years-20 (34.5%) 39-41 years-16 (27.6%) 42-44 years-22 (37.9%)Gender Distribution Male-50 (86.2%) Female-8 (13.8%)Eye Laterality Right Eye (OD)-19 (32.8%) Left Eye (OS)-39 (67.2%)Duration of Onset8.8±1.3 days- 7 days-8 (13.8%) 8 days-16 (27.6%) 9 days-21 (36.2%) 10 days-9 (15.5%) 11-14 days-4 (6.9%) Baseline demographics and clinical characteristics All eyes showed FFA leakage (100%), predominantly the ink-blot pattern (72.4%), followed by smoke-stack (25.9%). SRF was universal (100%); the mean CMT was high (540.3 ± 146.5 µm) with one-third > 600 µm (31.0%) [Tables 2 and 3]. The mean ICGA hyperpermeability area measured 9.62 ± 5.70 mm²; the mean SFCT was 476.8 ± 102.5 µm, and the overall vortex vein diameter was 1.39 ± 0.17 mm, indicating marked pachychoroid features [Table 4]. Table 2Baseline imaging characteristicsParameterValuen (%)FFA Leakage Present-58 (100%)Leakage Patterns Ink Blot-42 (72.4%) Smoke Stack-15 (25.9%) Diffuse Pattern-1 (1.7%)Subretinal Fluid Present-58 (100%)Central Macular Thickness (μm)540.3±146.5- <500 μm-21 (36.2%) 500-600 μm-19 (32.8%) >600 μm-18 (31.0%)ICGA Hyperpermeability Area (mm²)9.62±5.70-Subfoveal Choroidal Thickness (μm)476.8±102.5-Overall Vortex Vein Diameter (mm)1.39 0.17- Baseline imaging characteristics Table 3Visual and structural outcomes at 12 WeeksParameterBaselinePost 12 WeeksChange P BCVA (LogMAR) Mean±SD0.24±0.100.08±0.06-0.16±0.09<0.001* Range0.08-0.480.00-0.26-BCVA Categories 0.000 (0%)4 (6.9%)-<0.001* 0.02-0.1623 (39.7%)38 (65.5%)- 0.18-0.2617 (29.3%)16 (27.6%)- 0.28-0.4818 (31.0%)0 (0%)-Central Macular Thickness (μm) Mean±SD540.3±146.5271.3±23.3-269.0±145.2<0.001* Range416-887242-384-645 to -32CMT Categories <500 μm21 (36.2%)55 (94.8%)-<0.001* >600 μm18 (31.0%)3 (5.2%)-Subretinal Fluid Resolution SRF Present58 (100%)8 (13.8%)-<0.001* SRF Absent0 (0%)50 (86.2%)- Complete Resolution Rate-86.2%- Visual and structural outcomes at 12 Weeks Table 4Advanced imaging parameters at 12 WeeksParameterBaselinePost 12 WeeksChange P ICGA Hyperpermeability Area (mm²) Mean±SD9.62±5.706.47±4.32-3.15±4.28<0.001* Range1.8-18.21.20-13.40-8.8 to +1.2 Median8.006.30-1.70Subfoveal Choroidal Thickness (μm) Mean±SD476.8±102.5391.6±24.8-85.2±103.4<0.001* Range298-764292-458-272 to +166Vortex Vein Ampulla Diameter (mm) Supero-Nasal1.20±0.071.17±0.07-0.03±0.08>0.05 Supero-Temporal1.30±0.121.26±0.13-0.04±0.12>0.05 Infero-Nasal1.46±0.121.41±0.12-0.05±0.11>0.05 Infero-Temporal1.60±0.161.56±0.17-0.04±0.15>0.05 Overall Mean1.39±0.171.35±0.16-0.04±0.12>0.05 Advanced imaging parameters at 12 Weeks BCVA improved significantly from 0.24 ± 0.10 to 0.08 ± 0.06 LogMAR (Δ = −0.16 ± 0.09; P < 0.001), with category shifts toward better vision (6.9% at 0.00 LogMAR; elimination of the poorest 0.28–0.48 LogMAR group) [Table 2]. CMT fell from 540.3 ± 146.5 to 271.3 ± 23.3 µm (Δ = −269.0 ± 145.2 µm; P < 0.001), and the proportion with CMT < 500 µm rose from 36.2% to 94.8% (P < 0.001). SRF resolved in 86.2% of eyes (P < 0.001), indicating robust anatomical and functional response[11] [Table 3]. The ICGA hyperpermeability area significantly decreased (9.62 ± 5.70 to 6.47 ± 4.32 mm²; Δ = −3.15 ± 4.28; P < 0.001) [Table 4] [Figs. 3 and 4], and SFCT reduced (476.8 ± 102.5 to 391.6 ± 24.8 µm; Δ = −85.2 ± 103.4; P < 0.001) [Table 3]. Vortex vein ampulla diameters showed small, nonsignificant quadrant-wise reductions (overall 1.39 ± 0.17 to 1.35 ± 0.16 mm; P > 0.05) [Table 4] [Figs. 6 and 7], suggesting a trend toward improved choroidal venous outflow without statistical significance. Discussion The principal finding of this study is that 12 weeks of oral eplerenone therapy is associated with a significant quantitative reduction in the area of choroidal hyperpermeability in patients with acute CSCR. Using UWF-ICGA, we observed a mean reduction in the hyperpermeable area from 9.62 ± 5.70 to 6.47 ± 4.32 mm² (Δ = −3.15 ± 4.28; P < 0.001). This structural improvement in the ‘pachychoroid’ vasculature was accompanied by significant clinical resolution, with a mean decrease in central macular thickness (CMT) from 540.3 ± 146.5 to 271.3 ± 23.3 µm (Δ = −269.0 ± 145.2 µm; P < 0.001). Our cohort was characterized by a young demographic (mean age 39.9 ± 2.6 years) presenting with a short disease duration (mean 8.8 ± 1.3 days). This differs from previous studies, such as Sharma et al., where the comparable mean age (39.15 years) was associated with a much wider dispersion of disease duration, reflecting the inclusion of more chronic phenotypes. While spontaneous resolution is common in acute CSCR, the panoramic visualization provided by UWF-ICGA suggests that MR antagonism may actively modulate the peripheral choroidal congestion and venous dilation that define the pachychoroid spectrum. The significant reduction in choroidal hyperpermeability area observed in our study highlights the specific role of eplerenone in modulating the ‘pachychoroid’ state. In CSCR, overactivation of MR in the choroidal endothelium is hypothesized to upregulate vasodilatory ion channels, specifically the calcium-dependent potassium channels (KCa2.3). This results in the characteristic venous dilation, congestion, and hydrostatic leakage seen on ICGA. By acting as a competitive MR antagonist, eplerenone likely inhibits these pathways, leading to a measurable ‘de-congestion’ and reduction in the area of hyperpermeability (mm2).[47] The novelty of this investigation lies in the application of UWF imaging. Conventional ICGA provides a limited 30–50-degree view, which focuses primarily on the posterior pole. However, our findings demonstrate that the vascular remodeling associated with eplerenone therapy extends into the mid- and far-periphery. The usefulness of UWF-ICGA as a panoramic biomarker is evident in its ability to quantify global choroidal changes, offering a more comprehensive assessment of the ‘sick choroid’ than standard imaging.[3] This panoramic visualization is essential for monitoring diseases in the pachychoroid spectrum, where peripheral venous congestion is a key pathological feature. Visual acuity (VA) outcomes: BCVA improved from 0.24 ± 0.10 to 0.08 ± 0.06 LogMAR at 12 weeks (~0.16 LogMAR gain), with 6.9% reaching 0.00 LogMAR and two-thirds achieving 0.02–0.16 LogMAR. Sharma et al.[11] reported more dramatic gains (96.2% at 6/6 in the eplerenone arm vs 19.2% in controls), differences that may reflect baseline VA, inclusion of a comparator arm, and methodological nuances. In chronic cohorts, improvement is common but slower: 88.2% improved by 12 months in Karagiannis et al.[12] without granular LogMAR data. Notably, the randomized, double-blind VICI trial (Lotery et al.[13]) found no superiority of eplerenone over placebo at 12 months (79.5 vs 80.4 letters; P = 0.24), likely influenced by chronic disease mix and limited headroom for VA gains. Taken together, our acute-leaning cohort and the time horizon (12 weeks) may explain larger early functional gains relative to chronic, controlled settings. We enrolled 58 predominantly male patients (86.2%) with a narrow age range (mean 39.9 ± 2.6 years; 36–44 years), typical of CSCR epidemiology. Comparable mean ages have been reported (39.15 ± 12.1 years in the treatment arm of Sharma et al.[11]), though with wider dispersion, reflecting broader inclusion of acute and chronic phenotypes. Our short symptom duration (mean 8.8 ± 1.3 days) indicates an acute cohort, whereas Karagiannis et al.[12] focused on chronic CSCR, likely older or more heterogeneous populations. An unusual left-eye predominance (67.2%) contrasted with the more balanced laterality in Sharma et al.[11] and probably reflects sampling variation in a modest-sized series. CMT fell markedly from 540.3 ± 146.5 µm to 271.3 ± 23.3 µm (mean reduction 269.0 ± 145.2 µm), with a categorical shift from 36.2% to 94.8% below 500 µm by week 12. This scale of normalization is among the most pronounced in the eplerenone literature. Rabiolo et al. described structural improvements but without numerical CMT for direct benchmarking, while Faghihi et al. emphasized significant reductions in choroidal indices (subfoveal thickness and volumes) at 3 months rather than retinal thickness per se.[1415] The categorical collapse of the 500–600 µm band in our data suggests broad responsiveness across baseline severity, with only 5.2% remaining >600 µm—likely reflecting refractory or slower-responding eyes. SRF resolved in 86.2% at 12 weeks (13.8% persistent), outperforming the 12-week resolution proportion in Sharma et al.[11] (61.52% eplerenone vs 38.46% control), where spontaneous recovery in controls highlights CSCR’s self-limited biology. In chronic disease, Karagiannis et al.[12] reported 76.4% SRF resolution at 12 months, consistent with slower convalescence. Faghihi et al.[14] observed SRF reduction across acute and chronic subsets, with the largest relative decline in acute cases, mirroring our cohort composition and results. Rajesh et al.[9] found baseline VA predicted final VA and early SRF height weakly predicted later height, underscoring the value of early biomarkers to anticipate response and to counsel the ~14% who remained fluid-positive at 12 weeks. It is important to differentiate the observed improvements from the natural history of the disease. While spontaneous resolution of fluid is common in acute CSCR, the UWF-ICGA findings in our study provide a unique insight into the drug’s mechanism. The significant reduction in peripheral and macular choroidal hyperpermeability areas (mm2) suggests that eplerenone actively modulates the underlying choroidal vasculopathy. Natural history studies typically emphasize fluid resolution, but there is limited evidence that spontaneous recovery involves such rapid and extensive remodeling of the choroidal vascular hyperpermeability within 12 weeks. This supports the hypothesis that MR-antagonism specifically targets the dilated pachyvessels. We quantified a reduction in late hyperpermeability area from 9.62 ± 5.70 to 6.47 ± 4.32 mm² (median 8.00→6.30 mm²), providing direct evidence of choroidal vascular improvement with mineralocorticoid antagonism. While many series prioritize OCT endpoints, our ICGA metric addresses the pachychoroid vasculopathy that underlies CSCR. Akilesh et al.[16] cataloged UWF-ICGA hallmarks—pachyvessels, diffuse leakage, and late hypercyanescence—supporting the pathophysiologic relevance of our angiographic signal. The paucity of comparative, quantitative UWF-ICGA datasets limits cross-study validation but highlights the novelty of this endpoint. Mean Vortex vein ampulla diameters decreased across all quadrants (overall 1.39 ± 0.17→1.35 ± 0.16 mm), suggesting a global effect on choroidal venous drainage; to our knowledge, prior eplerenone studies have not reported this parameter, making it hypothesis-generating for venous outflow modulation. SFCT declined from 476.8 ± 102.5 to 391.6 ± 24.8 µm (≈18% reduction) with narrowing dispersion, consistent with choroidal normalization. Faghihi et al. similarly documented significant decreases in subfoveal and total choroidal metrics at 3 months, while Rabiolo et al. noted greater thickness reduction with PDT than with eplerenone, implying treatment-specific choroidal effects.[14] Beyond structure, Viggiano et al.[17] showed progressive improvement in choriocapillaris flow deficits in fellow eyes during eplerenone (28.9%→24.9% at 12 months), aligning with our structural improvements and supporting a perfusion-level mechanism. Although our series did not detail adverse events, other studies report generally good tolerability with 25–50 mg regimens. Sharma et al.[11] observed no adverse events and stable potassium (4.80 ± 0.157 mEq/L) at 12 weeks.[9] In VICI, hyperkalemia occurred in 14% of both eplerenone and placebo arms (no safety signal), whereas Karagiannis et al.[12] reported two discontinuations (hyperkalemia, rash) during a titrated course.[13] Overall, eplerenone appears safe with monitoring for electrolytes and renal function. In an acute-leaning CSCR cohort, eplerenone was associated with rapid functional gains, robust CMT normalization, high SRF resolution, and objective improvements in choroidal hyperpermeability, thickness, and vortex vein caliber. Discrepancies with the negative randomized data likely reflect chronicity, baseline VA, and natural history effects.[12] Quantitative UWF-ICGA and venous metrics may enrich future trials by capturing choroidal endpoints that mirror the drug’s mechanism. Further controlled studies stratified by disease stage and anchored to choroidal biomarkers are warranted to refine patient selection and expectations.[91013] A significant limitation of this study is the short-term follow-up of 12 weeks. While this duration was sufficient to observe a significant reduction in choroidal hyperpermeability and subretinal fluid, it does not allow for the assessment of long-term recurrence rates or the temporal stability of the vascular changes observed on UWF-ICGA. Serial, long-term ICGA imaging would be required to determine if the suppression of choroidal hyperpermeability is maintained after the cessation of oral mineralocorticoid receptor (MR) antagonists. Future longitudinal studies are warranted to correlate these early 12-week vascular markers with long-term visual outcomes. This was not a randomized controlled trial, and due to the observational pilot design of the study and the lack of a control group, the improvements in both structural and functional parameters cannot be definitively and exclusively attributed to eplerenone therapy. However, the measurable changes in UWF-ICGA hyperpermeability provide a compelling structural correlate for the clinical improvement observed. The potential for overlap with the natural history of acute CSCR remains a confounding factor that warrants further validation through randomized, double-blinded, placebo-controlled trials. Further, the study is limited by the absence of a control group of healthy eyes or normative data for choroidal hyperpermeability areas. Currently, the Optos Advance system does not provide built-in normative databases for ICGA planimetry, and geographic variations in choroidal thickness and vascularity make external comparisons challenging. Furthermore, while the fellow unaffected eyes were screened qualitatively and showed similar vascular symmetry in some cases, quantitative measurements were not recorded as per the primary study protocol. The lack of a baseline comparison for ‘normal’ hyperpermeability area is a limitation that may affect the absolute interpretation of these vascular zones. Conclusion Eplerenone therapy led to significant anatomical and functional improvement in acute CSCR over 12 weeks. UWFI ICGA provided valuable insights into choroidal vascular remodeling, demonstrating reduction in hyperpermeability areas and vortex vein diameters, correlating with SRF resolution and visual recovery. These findings support the role of MR antagonism in CSCR pathophysiology and highlight UWFI ICGA as a sensitive modality to monitor therapeutic response. Conflicts of interest There are no conflicts of interest.